The top 100 biotech VCs: Who's stay­ing at the ta­ble and what do they want now?

As we all know on­ly too well, the old play­book on biotech in­vest­ing got thrown out the win­dow with the end of the IPO boom at the be­gin­ning of 2022. We re­cent­ly tracked VCs’ per­for­mance last year and list­ed the top 100 play­ers in the field. And then I gath­ered a group of top VCs to talk about how it’s all work­ing in 2023. Here’s our con­ver­sa­tion.

This tran­script has been edit­ed for brevi­ty and clar­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.